{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:40:26Z","timestamp":1787755226245,"version":"build-2784847793"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007816","name":"Alcon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007816","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40123-026-01421-1","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T05:52:05Z","timestamp":1784353925000},"page":"3025-3039","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Improvement in Visual-Tasking Daily Living Activities and Work Productivity in Patients with Dry Eye Disease: Integrated Analysis of COMET Studies"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct04498182","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05285644","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05360966","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9036-5158","authenticated-orcid":false,"given":"Laura M.","family":"Periman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0857-1003","authenticated-orcid":false,"given":"Cory J.","family":"Lappin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5738-6918","authenticated-orcid":false,"given":"Marguerite B.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7348-4647","authenticated-orcid":false,"given":"Jade","family":"Coats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1534-554X","authenticated-orcid":false,"given":"Guruprasad R.","family":"Pattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6522-2199","authenticated-orcid":false,"given":"Tony","family":"Okoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0577-2774","authenticated-orcid":false,"given":"Nathan","family":"Lighthizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8909-6843","authenticated-orcid":false,"given":"Michelle","family":"Senchyna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9096-7631","authenticated-orcid":false,"given":"Lisa M.","family":"Nijm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,18]]},"reference":[{"key":"1421_CR1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ajo.2025.05.033","volume":"279","author":"JS Wolffsohn","year":"2025","unstructured":"Wolffsohn JS, Benitez-Del-Castillo JM, Loya-Garcia D, et al. TFOS DEWS III: diagnostic methodology. Am J Ophthalmol. 2025;279:387\u2013450. https:\/\/doi.org\/10.1016\/j.ajo.2025.05.033.","journal-title":"Am J Ophthalmol"},{"key":"1421_CR2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jtos.2023.04.004","volume":"28","author":"JS Wolffsohn","year":"2023","unstructured":"Wolffsohn JS, Lingham G, Downie LE, et al. TFOS Lifestyle: impact of the digital environment on the ocular surface. Ocul Surf. 2023;28:213\u201352. https:\/\/doi.org\/10.1016\/j.jtos.2023.04.004.","journal-title":"Ocul Surf"},{"key":"1421_CR3","unstructured":"2024 Dry eye products market report: a global analysis for 2023 to 2029. 2024. https:\/\/www.market-scope.com\/pages\/reports. Market Scope."},{"key":"1421_CR4","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jtos.2023.04.006","volume":"28","author":"F Stapleton","year":"2023","unstructured":"Stapleton F, Abad JC, Barabino S, et al. TFOS Lifestyle: impact of societal challenges on the ocular surface. Ocul Surf. 2023;28:165\u201399. https:\/\/doi.org\/10.1016\/j.jtos.2023.04.006.","journal-title":"Ocul Surf"},{"issue":"7","key":"1421_CR5","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1097\/ICO.0000000000002580","volume":"40","author":"RR Sayegh","year":"2021","unstructured":"Sayegh RR, Yu Y, Farrar JT, et al. Ocular discomfort and quality of life among patients in the Dry Eye Assessment and Management Study. Cornea. 2021;40(7):869\u201376. https:\/\/doi.org\/10.1097\/ICO.0000000000002580.","journal-title":"Cornea"},{"issue":"1","key":"1421_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2021-000709","volume":"6","author":"C Chan","year":"2021","unstructured":"Chan C, Ziai S, Myageri V, Burns JG, Prokopich CL. Economic burden and loss of quality of life from dry eye disease in Canada. BMJ Open Ophthalmol. 2021;6(1):e000709. https:\/\/doi.org\/10.1136\/bmjophth-2021-000709.","journal-title":"BMJ Open Ophthalmol"},{"issue":"5","key":"1421_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3238\/arztebl.2015.0071","volume":"112","author":"EM Messmer","year":"2015","unstructured":"Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int. 2015;112(5):71\u201381. https:\/\/doi.org\/10.3238\/arztebl.2015.0071.","journal-title":"Dtsch Arztebl Int"},{"key":"1421_CR8","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jtos.2023.04.008","volume":"28","author":"A Galor","year":"2023","unstructured":"Galor A, Britten-Jones AC, Feng Y, et al. TFOS Lifestyle: impact of lifestyle challenges on the ocular surface. Ocul Surf. 2023;28:262\u2013303. https:\/\/doi.org\/10.1016\/j.jtos.2023.04.008.","journal-title":"Ocul Surf"},{"issue":"12","key":"1421_CR9","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1038\/s41433-020-01282-3","volume":"35","author":"GK Sivakumar","year":"2021","unstructured":"Sivakumar GK, Patel J, Malvankar-Mehta MS, Mather R. Work productivity among Sj\u00f6gren\u2019s syndrome and non-Sj\u00f6gren\u2019s dry eye patients: a systematic review and meta-analysis. Eye (Lond). 2021;35(12):3243\u201357. https:\/\/doi.org\/10.1038\/s41433-020-01282-3.","journal-title":"Eye (Lond)"},{"issue":"3","key":"1421_CR10","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.ajo.2006.11.060","volume":"143","author":"B Miljanovic","year":"2007","unstructured":"Miljanovic B, Dana R, Sullivan DA, Schaumberg DA. Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol. 2007;143(3):409\u201315. https:\/\/doi.org\/10.1016\/j.ajo.2006.11.060.","journal-title":"Am J Ophthalmol"},{"key":"1421_CR11","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.2147\/OPTH.S321591","volume":"15","author":"Z Al-Mohtaseb","year":"2021","unstructured":"Al-Mohtaseb Z, Schachter S, Shen Lee B, Garlich J, Trattler W. The relationship between dry eye disease and digital screen use. Clin Ophthalmol. 2021;15:3811\u201320. https:\/\/doi.org\/10.2147\/OPTH.S321591.","journal-title":"Clin Ophthalmol"},{"issue":"6","key":"1421_CR12","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1097\/OPX.0000000000001086","volume":"94","author":"MM van Tilborg","year":"2017","unstructured":"van Tilborg MM, Murphy PJ, Evans KS. Impact of dry eye symptoms and daily activities in a modern office. Optom Vis Sci. 2017;94(6):688\u201393. https:\/\/doi.org\/10.1097\/OPX.0000000000001086.","journal-title":"Optom Vis Sci"},{"issue":"4","key":"1421_CR13","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/bjophthalmol-2015-308237","volume":"101","author":"PM Mathews","year":"2017","unstructured":"Mathews PM, Ramulu PY, Swenor BS, Utine CA, Rubin GS, Akpek EK. Functional impairment of reading in patients with dry eye. Br J Ophthalmol. 2017;101(4):481\u20136. https:\/\/doi.org\/10.1136\/bjophthalmol-2015-308237.","journal-title":"Br J Ophthalmol"},{"key":"1421_CR14","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ajo.2025.05.040","volume":"279","author":"F Stapleton","year":"2025","unstructured":"Stapleton F, Argueso P, Asbell P, et al. TFOS DEWS III: digest. Am J Ophthalmol. 2025;279:451\u2013553. https:\/\/doi.org\/10.1016\/j.ajo.2025.05.040.\u00a0[Erratum in: Am J Ophthalmol. 2026:S0002-9394(26)00202-3. doi: 10.1016\/j.ajo.2026.04.007]","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"1421_CR15","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ophtha.2020.10.015","volume":"128","author":"G Greco","year":"2021","unstructured":"Greco G, Pistilli M, Asbell PA, Maguire MG, Dry Eye Assessment and Management Study Research Group. Association of severity of dry eye disease with work productivity and activity impairment in the Dry Eye Assessment and Management Study. Ophthalmology. 2021;128(6):850\u20136. https:\/\/doi.org\/10.1016\/j.ophtha.2020.10.015.","journal-title":"Ophthalmology"},{"issue":"7","key":"1421_CR16","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1167\/iovs.16-19419","volume":"57","author":"KK Nichols","year":"2016","unstructured":"Nichols KK, Bacharach J, Holland E, et al. Impact of dry eye disease on work productivity, and patients\u2019 satisfaction with over-the-counter dry eye treatments. Invest Ophthalmol Vis Sci. 2016;57(7):2975\u201382. https:\/\/doi.org\/10.1167\/iovs.16-19419.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1421_CR17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jtos.2021.05.006","volume":"21","author":"MK Morthen","year":"2021","unstructured":"Morthen MK, Magno MS, Utheim TP, Snieder H, Hammond CJ, Vehof J. The physical and mental burden of dry eye disease: a large population-based study investigating the relationship with health-related quality of life and its determinants. Ocul Surf. 2021;21:107\u201317. https:\/\/doi.org\/10.1016\/j.jtos.2021.05.006.","journal-title":"Ocul Surf"},{"issue":"4","key":"1421_CR18","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/ICO.0b013e3181f7f363","volume":"30","author":"J Yu","year":"2011","unstructured":"Yu J, Asche CV, Fairchild CJ. The economic burden of dry eye disease in the United States: a decision tree analysis. Cornea. 2011;30(4):379\u201387. https:\/\/doi.org\/10.1097\/ICO.0b013e3181f7f363.","journal-title":"Cornea"},{"issue":"3","key":"1421_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-039209","volume":"11","author":"P Hossain","year":"2021","unstructured":"Hossain P, Siffel C, Joseph C, Meunier J, Markowitz JT, Dana R. Patient-reported burden of dry eye disease in the UK: a cross-sectional web-based survey. BMJ Open. 2021;11(3):e039209. https:\/\/doi.org\/10.1136\/bmjopen-2020-039209.","journal-title":"BMJ Open"},{"issue":"2","key":"1421_CR20","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1001\/archophthalmol.2008.608","volume":"127","author":"MM Brown","year":"2009","unstructured":"Brown MM, Brown GC, Brown HC, Peet J, Roth Z. Value-based medicine, comparative effectiveness, and cost-effectiveness analysis of topical cyclosporine for the treatment of dry eye syndrome. Arch Ophthalmol. 2009;127(2):146\u201352. https:\/\/doi.org\/10.1001\/archophthalmol.2008.608.","journal-title":"Arch Ophthalmol"},{"key":"1421_CR21","unstructured":"Tryptyr\u00ae (acoltremon ophthalmic solution) 0.003%. Prescribing information. Alcon Laboratories Inc. Fort Worth, TX. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/217370s000lbl.pdf."},{"key":"1421_CR22","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jtos.2025.07.003","volume":"38","author":"J Gallar","year":"2025","unstructured":"Gallar J, Pflugfelder S, Galor A, Gupta PK, Hamrah P. Corneal sensory nerve regulation of tear production through stimulation of transient receptor potential melastatin 8 (TRPM8) channel: a potential new approach for treating dry eye disease. Ocul Surf. 2025;38:142\u201354. https:\/\/doi.org\/10.1016\/j.jtos.2025.07.003.","journal-title":"Ocul Surf"},{"issue":"5","key":"1421_CR23","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ophtha.2025.09.018","volume":"133","author":"GR Pattar","year":"2026","unstructured":"Pattar GR, Wirta D, Jerkins G, et al. Acoltremon ophthalmic solution 0.003% for signs and symptoms of dry eye disease: results of phase\u00a03 pivotal studies COMET-2 and COMET-3. Ophthalmology. 2026;133(5):563\u201374. https:\/\/doi.org\/10.1016\/j.ophtha.2025.09.018.","journal-title":"Ophthalmology"},{"key":"1421_CR24","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jtos.2022.08.003","volume":"26","author":"DL Wirta","year":"2022","unstructured":"Wirta DL, Senchyna M, Lewis AE, et al. A randomized, vehicle-controlled, phase\u00a02b study of two concentrations of the TRPM8 receptor agonist AR-15512 in the treatment of dry eye disease (COMET-1). Ocul Surf. 2022;26:166\u201373. https:\/\/doi.org\/10.1016\/j.jtos.2022.08.003.","journal-title":"Ocul Surf"},{"key":"1421_CR25","unstructured":"McGee SR, Koetting C, Evans DG, Senchyna M. Acoltremon 0.003% leads to reductions in both the frequency and severity of dry eye symptoms within 14 days: integrated analysis of COMET studies. Presented at: American Academy of Optometry 2025 Annual Meeting; October 8\u201311, 2025; Boston, MA."},{"issue":"5","key":"1421_CR26","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1213\/ANE.0000000000002864","volume":"126","author":"P Schober","year":"2018","unstructured":"Schober P, Boer C, Schwarte LA. Correlation coefficients: appropriate use and interpretation. Anesth Analg. 2018;126(5):1763\u20138. https:\/\/doi.org\/10.1213\/ANE.0000000000002864.","journal-title":"Anesth Analg"},{"key":"1421_CR27","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2147\/OPTH.S188314","volume":"13","author":"JL Bradley","year":"2019","unstructured":"Bradley JL, Ozer Stillman I, Pivneva I, Guerin A, Evans AM, Dana R. Dry eye disease ranking among common reasons for seeking eye care in a large US claims database. Clin Ophthalmol. 2019;13:225\u201332. https:\/\/doi.org\/10.2147\/OPTH.S188314.","journal-title":"Clin Ophthalmol"},{"issue":"5","key":"1421_CR28","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1185\/03007995.2011.566264","volume":"27","author":"VD Patel","year":"2011","unstructured":"Patel VD, Watanabe JH, Strauss JA, Dubey AT. Work productivity loss in patients with dry eye disease: an online survey. Curr Med Res Opin. 2011;27(5):1041\u20138. https:\/\/doi.org\/10.1185\/03007995.2011.566264.","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"1421_CR29","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/S0161-6420(03)00462-7","volume":"110","author":"RM Schiffman","year":"2003","unstructured":"Schiffman RM, Walt JG, Jacobsen G, Doyle JJ, Lebovics G, Sumner W. Utility assessment among patients with dry eye disease. Ophthalmology. 2003;110(7):1412\u20139. https:\/\/doi.org\/10.1016\/S0161-6420(03)00462-7.","journal-title":"Ophthalmology"},{"issue":"1","key":"1421_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59010025","volume":"59","author":"G Martinescu","year":"2022","unstructured":"Martinescu G, Bogdanici CM, Pavel IA, Ciocoiu M. Difficulties in performing daily activities in patients with dry eye before and after treatment. Medicina (Kaunas). 2022;59(1):25. https:\/\/doi.org\/10.3390\/medicina59010025.","journal-title":"Medicina (Kaunas)"},{"key":"1421_CR31","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.2147\/OPTH.S469300","volume":"18","author":"Y Feng","year":"2024","unstructured":"Feng Y, Venkateswaran N, Steele A, Rosenberg ED, Gupta PK. Impact of TearCare on reading speed in patients with dry eye disease. Clin Ophthalmol. 2024;18:2873\u20138. https:\/\/doi.org\/10.2147\/OPTH.S469300.","journal-title":"Clin Ophthalmol"},{"issue":"10","key":"1421_CR32","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1097\/ICO.0000000000002633","volume":"40","author":"JD Sheppard","year":"2021","unstructured":"Sheppard JD, Wirta DL, McLaurin E, et al. A water-free 0.1% cyclosporine A solution for treatment of dry eye disease: results of the randomized phase\u00a02B\/3 ESSENCE Study. Cornea. 2021;40(10):1290\u20137. https:\/\/doi.org\/10.1097\/ICO.0000000000002633.","journal-title":"Cornea"},{"issue":"6","key":"1421_CR33","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.ophtha.2019.01.024","volume":"126","author":"DL Wirta","year":"2019","unstructured":"Wirta DL, Torkildsen GL, Moreira HR, et al. A clinical phase\u00a0II study to assess efficacy, safety, and tolerability of waterfree cyclosporine formulation for treatment of dry eye disease. Ophthalmology. 2019;126(6):792\u2013800. https:\/\/doi.org\/10.1016\/j.ophtha.2019.01.024.","journal-title":"Ophthalmology"},{"issue":"7","key":"1421_CR34","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","volume":"119","author":"CM Mangione","year":"2001","unstructured":"Mangione CM, Lee PP, Gutierrez PR, et al. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119(7):1050\u20138. https:\/\/doi.org\/10.1001\/archopht.119.7.1050.","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"1421_CR35","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1001\/archopht.118.5.615","volume":"118","author":"RM Schiffman","year":"2000","unstructured":"Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease\u00a0Index. Arch Ophthalmol. 2000;118(5):615\u201321. https:\/\/doi.org\/10.1001\/archopht.118.5.615.","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"1421_CR36","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1097\/ICO.0b013e318294b0c0","volume":"32","author":"W Ngo","year":"2013","unstructured":"Ngo W, Situ P, Keir N, Korb D, Blackie C, Simpson T. Psychometric properties and validation of the Standard Patient Evaluation of Eye Dryness questionnaire. Cornea. 2013;32(9):1204\u201310. https:\/\/doi.org\/10.1097\/ICO.0b013e318294b0c0.","journal-title":"Cornea"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01421-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01421-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01421-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:39:40Z","timestamp":1787751580000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01421-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,18]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1421"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01421-1","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,18]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Laura M. Periman reports consulting, speaking, and advisory relationships with Alcon, Aldeyra Therapeutics, Allergan\/AbbVie, Amgen, Azura Ophthalmics, Bausch\u2009+\u2009Lomb, Domp\u00e9, Eyedetec, Harrow, Jett, KALA BIO, Lumenis, Mallinckrodt, MD Elite, Myze, Nordic Pharma, NuSight Medical, NuVissa, Olympic Ophthalmics, Quench Method, Science Based Health, SCOPE, Sun Pharma, and Tarsus; serves as a principal investigator for studies sponsored by Alcon, Bausch\u2009+\u2009Lomb, KALA BIO, Lumenis, Olympic Ophthalmics, and Tarsus; and holds equity in Eyedetec, Harrow, Myze, NuSight Medical, and Quench Method. Cory J. Lappin reports consulting fees and\/or honoraria from Alcon, Barti, Bausch\u2009+\u2009Lomb, Bruder Healthcare and M&S Technologies (Hilco Vision), EyePromise\/PRN, Harrow, Lumenis, Norwood Device & Diagnostics, SCOPE Health, Sight Sciences, TearRestore, Tarsus, Domp\u00e9, and Viatris; serves on advisory boards for Bruder Healthcare and M&S Technologies (Hilco Vision), Eyenovia, EyePromise\/PRN, Harrow, Myze, Nordic Pharma, Tarsus, and Vital Tears; participates on Data Safety Monitoring Boards for Alcon and Bausch\u2009+\u2009Lomb; has received travel support from MJH Life Sciences\/Physicians\u2019 Education Resource; holds leadership roles with Optometric Physician, Eyes On Eyecare, Optometry 360, the Ohio Optometric Association, and the Arizona Optometric Association; and holds equity in Barti, Eyederm, Myze, and NuLids. Marguerite B. McDonald reports, as her only relevant conflict, receiving consulting fees and\/or honoraria from Alcon as well as participation on a data safety monitoring board or advisory board for Alcon. Jade Coats reports service on advisory boards and\/or speakers\u2019 bureaus for AbbVie, Alcon, Bausch & Lomb, Domp\u00e9, Harrow, LENZ Therapeutics, Novaliq, Orasis Pharmaceuticals, Sun Pharma, Tarsus, Tenpoint Therapeutics, Thea, Trukera, Viatris, and Zeiss. Guruprasad R. Pattar reports no conflicts of interest. Tony Okoro is an employee of Alcon and reports holding stock or stock options in Alcon. Nathan Lighthizer reports consulting fees from OCuSOFT, Visionix, Virtual Vision, and Orasis Pharmaceuticals, and honoraria for lectures, presentations, speakers\u2019 bureaus, or educational activities from Alcon, Bausch & Lomb, Sun Pharma, Tarsus, Innova Systems, AbbVie, Domp\u00e9, EyePromise, LKC, and Lumenis. Michelle Senchyna was an employee of Alcon at the time of the study and reports holding stock or stock options in Alcon. Lisa M. Nijm reports consulting, speaking, and advisory relationships with Alcon, Allergan, Amgen, Apellis, Astellas, Azura Ophthalmics, Bausch\u2009+\u2009Lomb, Bruder, BVI Medical, Domp\u00e9, Harrow, Johnson & Johnson Vision, Nordic Pharma, Ocular Therapeutix, Orasis Pharmaceuticals, Rayner, SCOPE Health, Sun Pharma, Tarsus, Trukera Medical, Thea, Viatris, Visus Therapeutics, Zeiss; has grants\/contracts from Ocular Therapeutix; and holds leadership or fiduciary roles in Women in Ophthalmology, the Cornea Society, the American Academy of Ophthalmology Executives, and the UIC Ophthalmology Alumni Council.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Each study (COMET-1, NCT04498182; COMET-2, NCT05285644; COMET-3, NCT05360966) was performed in compliance with the International Conference on Harmonisation Good Clinical Practice guidelines, the principles of the Declaration of Helsinki, US Food and Drug Administration regulations, and the standard operating procedures of the sponsor and vendors participating in the conduct of the study. Written informed consent was provided by all patients prior to enrollment, and an institutional review board (Alpha Institutional Review Board, San Clemente, CA, USA; IRB00006205) approved all forms provided directly to the patient prior to their use. This article is based on previously conducted studies and does not include any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}